Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gallium-68 NeoBOMB1 - Advanced Accelerator Applications

Drug Profile

Gallium-68 NeoBOMB1 - Advanced Accelerator Applications

Alternative Names: 68Ga-NeoBOMB1; [68Ga]Ga-NeoB

Latest Information Update: 10 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Erasmus University Rotterdam; National Center for Scientific Research Demokritos
  • Developer Advanced Accelerator Applications; Erasmus University Rotterdam
  • Class Imaging agents; Neuropeptides; Organometallic compounds; Peptides; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Bombesin receptor antagonists; Ionising radiation emitters; Neuropeptide receptor antagonists; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastrointestinal stromal tumours
  • New Molecular Entity No

Highest Development Phases

  • Phase II Breast cancer
  • Phase I/II Gastrointestinal stromal tumours; Solid tumours
  • Phase I Glioblastoma
  • No development reported Colorectal cancer; Non-small cell lung cancer; Prostate cancer; Small cell lung cancer

Most Recent Events

  • 10 May 2024 CTP Push 700361998 -KDM, DT, HE
  • 01 May 2024 Phase-I clinical trials in Glioblastoma (Newly diagnosed, Combination therapy, Recurrent) in Israel, Spain, Portugal (IV) (EudraCT2022-502134-10-00) (NCT05739942)
  • 08 Feb 2024 Novartis Pharmaceuticals plans a phase I/II trial for Breast cancer (Combination therapy, Metastatic disease, Second-line therapy or greater), in May 2024 (NCT06247995) (EudraCT2023-506717-21)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top